GLP-1 Medications for Weight Loss: How Semaglutide Works
The most effective non-surgical weight loss medication studied to date. Here is the clinical evidence — and who it is right for.
Quick answer: GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) mimic a gut hormone that regulates appetite and blood sugar. Clinical trials (NEJM STEP-1 trial, 2021) showed average 14.9% body weight reduction in 68 weeks — the most effective non-surgical weight loss medication ever studied.
What Is GLP-1?
Glucagon-like peptide-1 (GLP-1) is a hormone secreted by L-cells in the intestine in response to eating. Its physiological roles include:
- Stimulating insulin secretion in a glucose-dependent manner (only when blood sugar is elevated)
- Suppressing glucagon — the hormone that raises blood sugar
- Slowing gastric emptying — food moves more slowly through the stomach, prolonging satiety
- Signaling appetite centers in the brain (hypothalamus) to reduce hunger
Natural GLP-1 has a very short half-life — it is degraded by the enzyme DPP-4 within minutes. Synthetic GLP-1 receptor agonists were engineered to resist this degradation, allowing once-weekly dosing while maintaining prolonged receptor activity.
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist with 94% structural homology to human GLP-1, engineered with albumin binding and fatty acid chain modifications that extend its half-life to approximately 1 week. Administered as a weekly subcutaneous injection, it produces sustained GLP-1 receptor activation.
The appetite suppression effect is mediated centrally — semaglutide crosses the blood-brain barrier and acts directly on hypothalamic appetite-regulating centers. Patients consistently report reduced hunger, earlier satiety, and decreased interest in food, leading to spontaneous caloric reduction without deliberate dietary restriction.
The Clinical Evidence
| Trial | N | Duration | Semaglutide | Placebo |
|---|---|---|---|---|
| STEP-1 (NEJM, 2021) | 1,961 | 68 weeks | −14.9% body weight | −2.4% |
| STEP-2 (Lancet, 2021) | 1,210 | 68 weeks | −9.6% (type 2 DM) | −3.4% |
| STEP-3 (JAMA, 2021) | 611 | 68 weeks | −16.0% (intensive lifestyle) | −5.7% |
| STEP-4 | 803 | 68 weeks after run-in | Maintained −17.4% | +6.9% (after stopping) |
The STEP-4 trial finding is particularly important: it demonstrated that weight regain is substantial when semaglutide is discontinued. This confirms that obesity is a chronic, relapsing condition that benefits from long-term pharmacological management — not a short course of treatment.
Who Is a Candidate?
FDA approval criteria for Wegovy (semaglutide 2.4mg for weight management):
- Adults with BMI ≥30 (obesity), or
- Adults with BMI ≥27 plus at least one weight-related condition: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
A provider evaluation is required to determine clinical appropriateness. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pancreatitis history requires careful evaluation.
Side Effects and Dosing
The most common side effects are gastrointestinal. In STEP-1:
- Nausea: 44% (semaglutide) vs 16% (placebo)
- Diarrhea: 30% vs 16%
- Vomiting: 24% vs 6%
- Constipation: 24% vs 11%
Most GI effects are mild to moderate and decrease significantly over time with dose titration. The standard protocol starts at 0.25mg weekly and increases by 0.25mg every 4 weeks over approximately 16–20 weeks until reaching the maintenance dose. This gradual escalation is the primary strategy for tolerability.
A Note on Compounded vs Branded Semaglutide
During the FDA-declared semaglutide shortage period (2022–2024), compounding pharmacies were permitted to produce semaglutide under specific conditions. The FDA has indicated it is working to end shortage-based compounding as branded supply normalizes.
Affinity Direct providers will only prescribe semaglutide through appropriate channels — FDA-approved branded products (Wegovy, Ozempic) or compounded formulations only when legally permissible and clinically appropriate. We do not prescribe through channels that circumvent standard pharmaceutical oversight.
Common Questions
How much weight can you lose on semaglutide?
The STEP-1 trial showed an average body weight reduction of 14.9% at 68 weeks with semaglutide 2.4mg, versus 2.4% for placebo. 86% of semaglutide patients lost ≥5% of body weight. Individual results vary based on starting weight, adherence, diet, and lifestyle. Results require consistent weekly dosing.
Is semaglutide the same as Ozempic?
Semaglutide is the active ingredient in both Ozempic and Wegovy. Ozempic (up to 2mg weekly) is FDA-approved for type 2 diabetes. Wegovy (2.4mg weekly) is approved for chronic weight management. Both contain the same molecule — the difference is the approved indication and maximum dose.
How do GLP-1 injections work?
GLP-1 is a gut hormone released after eating that reduces appetite, slows gastric emptying, and improves insulin sensitivity. Semaglutide mimics GLP-1 with a half-life of ~1 week, allowing once-weekly dosing. It acts on hypothalamic appetite centers in the brain, producing significant and sustained reduction in hunger and caloric intake.
What are the side effects of semaglutide?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. Most are mild to moderate and resolve over time with the dose titration protocol (starting low and gradually increasing over 16–20 weeks). Rare but serious concerns include pancreatitis and a contraindication for patients with a personal or family history of medullary thyroid carcinoma.
Do you gain weight back after stopping semaglutide?
Yes. The STEP-4 trial showed that patients who stopped semaglutide regained approximately two-thirds of their lost weight within 48 weeks. This reflects the chronic nature of obesity — semaglutide is a long-term treatment for a chronic condition, similar to how blood pressure medication is used for hypertension. Most patients should expect to continue treatment indefinitely to maintain results.
GLP-1 weight loss is coming to Affinity Direct
Join the waitlist to be notified when our clinically supervised weight loss program launches — licensed providers, ongoing monitoring, delivered to your door.
Join the Waitlist →This article is written and reviewed by the Affinity Direct clinical team for informational purposes. It does not constitute medical advice. All prescriptions require a provider evaluation. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Last reviewed: March 2025.